Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

British Journal of Dermatology

Volumn 169, Issue 2, 2013, Pages 458-463

  Talamonti, M ^a   Botti, E ^a   Galluzzo, M ^a   Teoli, M ^a   Spallone, G ^a   Bavetta, M ^a   Chimenti, S ^a   Costanzo, A ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA CW6 ANTIGEN; LATE CORNIFIED ENVELOPE 3C; LATE CORNIFIED ENVELOPE B3; PEPTIDES AND PROTEINS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG; USTEKINUMAB;

ADULT; AGED; ALLELE; ARTICLE; DRUG RESPONSE; FEMALE; GENE DELETION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; CORNIFIED ENVELOPE PROLINE-RICH PROTEINS; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; HLA-C ANTIGENS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSORIASIS; YOUNG ADULT;

EID: 84881598576     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12331     Document Type: Article

References (22)

1. Nestle FO, Kaplan DH, Barker J,. Mechanisms of disease: psoriasis. N Engl J Med 2009; 361: 496-509.
2. Henseler T, Christophers E,. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-6.
3. Nickoloff BJ, Qin JZ, Nestle FO,. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007; 33: 45-56.
4. Bowcock AM, Krueger JG,. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-711.
5. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
6. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
7. Warren RB, Griffiths CE,. The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. Br J Dermatol 2005; 153: 869-73.
8. Tzu J, Kerdel F,. From conventional to cutting edge: the new era of biologics in treatment of psoriasis. Dermatol Ther 2008; 21: 131-41.
9. Hébert HL, Ali FR, Bowes J, et al,. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 2012; 166: 474-82.
10. Gulliver W,. HLA-Cw6 polymorphism predict response to the biologic therapy efalizumab in patients with chronic plaque psoriasis. J Am Acad Dermatol 2009; 60 (Suppl. 1): AB162.
11. Costanzo A, Spallone G, Talamonti M, et al,. New developments in the pharmacogenetics of psoriasis: HLA-Cw6 as a marker for the treatment of psoriasis with biological therapies. Adv Psoriasis Inflam Skin Dis 2011; 1: 125-30.
12. Tejasvi T, Stuart PE, Chandran V, et al,. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012; 132: 593-600.
13. de Cid R, Riveira-Munoz E, Zeeuwen PL, et al,. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009; 41: 211-15.
14. Nair RP, Ding J, Duffin KC, et al,. Psoriasis bench to bedside: genetics meets immunology. Arch Dermatol 2009; 145: 462-4.
15. Res PCM, Piskin G, de Boer OJ, et al,. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 2010; 5: e14108.
16. Ciric B, El-behi M, Cabrera R, et al,. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009; 182: 5296-305.
17. Nair RP, Duffin KC, Helms C, et al,. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199-204.
18. Opipari AW Jr, Boguski MS, Dixit VM,. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 1990; 265: 14705-8.
19. Wertz IE, O'Rourke KM, Zhou H, et al,. De-ubiquitination and ubiquitin ligase domain of A20 downregulate NF-κB signalling. Nature 2004; 430: 694-9.
20. Li L, Soetandyo N, Wang Q, Ye Y,. The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim Biophys Acta 2009; 1793: 346-53.
21. Jackson B, Tilli CM, Hardman MJ, et al,. Late cornified envelope family in differentiating epithelia-response to calcium and ultraviolet irradiation. J Invest Dermatol 2005; 124: 1062-70.
22. Marshall D, Hardman MJ, Nield KM, et al,. Differentially expressed late constituents of the epidermal cornified envelope. Proc Natl Acad Sci USA 2001; 98: 13031-6.